Is your facility ready for FDA inspection? For over a year the agency had paused the practice of on-site inspections to reduce person-to-person contact during the Covid-19 pandemic. However, as of today that practice has come to end, with in-person domestic surveillance inspections having officially resumed for the Agency.

On Feb. 2, the FDA determined that beginning on Feb. 7, the agency will resume conducting domestic surveillance inspections across all sectors, citing the decline in COVID-19 cases across the country.

In addition to resuming the planning and conducting of domestic surveillance inspections on Feb. 7, the FDA will continue to conduct both foreign and domestic mission-critical inspections, as well as continue to leverage other tools available such as remote assessments.

FDA stated in their announcement that “throughout all these activities, the agency remains committed to the health and safety of its investigators and will provide the protection needed to safely inspect facilities and conduct investigations at the ports and in agency laboratories.”

Is your company prepared for an unexpected Agency inspection? With Accorto Regulatory Solutions, our team will help you achieve and maintain compliance with your industry’s standards and regulations quickly and efficiently. Tailoring our programs to fit your company’s personalized needs, resources, and budget, your personalized action plan will ensure your company is compliant without ever being more than you need – saving you time and money at every stage in your audit preparation. View our full list of audit preparation and support services and speak to an expert here.